Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes.

Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T

Oncotarget 7 (46) 74966-74978 [2016-11-15; online 2016-09-03]

Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis.

Advanced Mass Spectrometry Proteomics [Collaborative]

QC bibliography QC xrefs

PubMed 27589561

DOI 10.18632/oncotarget.11663

Crossref 10.18632/oncotarget.11663

11663

pmc PMC5342715